WO2022125654A1 - Methods for controlled induction of bioengineered neuroepithelial tissues and 3-d neuroepithelial tubes - Google Patents
Methods for controlled induction of bioengineered neuroepithelial tissues and 3-d neuroepithelial tubes Download PDFInfo
- Publication number
- WO2022125654A1 WO2022125654A1 PCT/US2021/062390 US2021062390W WO2022125654A1 WO 2022125654 A1 WO2022125654 A1 WO 2022125654A1 US 2021062390 W US2021062390 W US 2021062390W WO 2022125654 A1 WO2022125654 A1 WO 2022125654A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- neuroepithelial
- cells
- tissue
- neural
- bioengineered
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 105
- 230000006698 induction Effects 0.000 title description 4
- 230000004069 differentiation Effects 0.000 claims abstract description 53
- 210000000276 neural tube Anatomy 0.000 claims abstract description 29
- 210000001778 pluripotent stem cell Anatomy 0.000 claims abstract description 26
- 238000001727 in vivo Methods 0.000 claims abstract description 20
- 210000000461 neuroepithelial cell Anatomy 0.000 claims abstract description 20
- 230000001413 cellular effect Effects 0.000 claims abstract description 19
- 230000008520 organization Effects 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 122
- 239000000758 substrate Substances 0.000 claims description 108
- 239000002609 medium Substances 0.000 claims description 90
- 230000001537 neural effect Effects 0.000 claims description 74
- 230000003592 biomimetic effect Effects 0.000 claims description 61
- 238000000338 in vitro Methods 0.000 claims description 43
- 239000000017 hydrogel Substances 0.000 claims description 40
- 230000004956 cell adhesive effect Effects 0.000 claims description 30
- 102000015735 Beta-catenin Human genes 0.000 claims description 27
- 108060000903 Beta-catenin Proteins 0.000 claims description 27
- 229920001223 polyethylene glycol Polymers 0.000 claims description 26
- 239000002202 Polyethylene glycol Substances 0.000 claims description 25
- 238000012258 culturing Methods 0.000 claims description 22
- 238000012423 maintenance Methods 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 238000010899 nucleation Methods 0.000 claims description 15
- 230000011664 signaling Effects 0.000 claims description 15
- 210000000130 stem cell Anatomy 0.000 claims description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 108010082117 matrigel Proteins 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 239000003590 rho kinase inhibitor Substances 0.000 claims description 12
- 230000019552 anatomical structure morphogenesis Effects 0.000 claims description 11
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical group CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 102000004338 Transferrin Human genes 0.000 claims description 7
- 108090000901 Transferrin Proteins 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 239000012581 transferrin Substances 0.000 claims description 7
- 102000003693 Hedgehog Proteins Human genes 0.000 claims description 6
- 108090000031 Hedgehog Proteins Proteins 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- 238000004115 adherent culture Methods 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 102000001267 GSK3 Human genes 0.000 claims description 4
- 108060006662 GSK3 Proteins 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 229940043355 kinase inhibitor Drugs 0.000 claims description 4
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 4
- 235000011649 selenium Nutrition 0.000 claims description 4
- 229940091258 selenium supplement Drugs 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000007747 plating Methods 0.000 claims description 3
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 claims description 2
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 claims description 2
- 210000002161 motor neuron Anatomy 0.000 claims description 2
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims 2
- 210000001178 neural stem cell Anatomy 0.000 abstract description 27
- 210000001519 tissue Anatomy 0.000 description 160
- 230000014509 gene expression Effects 0.000 description 30
- 102000000905 Cadherin Human genes 0.000 description 26
- 108050007957 Cadherin Proteins 0.000 description 26
- 108050000637 N-cadherin Proteins 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 25
- 101150090422 gsk-3 gene Proteins 0.000 description 21
- 239000000463 material Substances 0.000 description 19
- 210000002220 organoid Anatomy 0.000 description 19
- 239000001963 growth medium Substances 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000010410 layer Substances 0.000 description 15
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 12
- 229930002330 retinoic acid Natural products 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- -1 small molecule compounds Chemical class 0.000 description 11
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 10
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 229940126864 fibroblast growth factor Drugs 0.000 description 10
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 238000000059 patterning Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 108010085895 Laminin Proteins 0.000 description 7
- 102000007547 Laminin Human genes 0.000 description 7
- 108010031318 Vitronectin Proteins 0.000 description 7
- 102100035140 Vitronectin Human genes 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000021164 cell adhesion Effects 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 description 7
- 210000001671 embryonic stem cell Anatomy 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000010287 polarization Effects 0.000 description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 6
- 101150081664 PAX6 gene Proteins 0.000 description 6
- 239000005700 Putrescine Substances 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229960001727 tretinoin Drugs 0.000 description 6
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 5
- 238000003559 RNA-seq method Methods 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000000151 deposition Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 230000003988 neural development Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- PQXINDBPUDNMPE-UHFFFAOYSA-N 5-(furan-2-yl)-n-(3-imidazol-1-ylpropyl)-1,2-oxazole-3-carboxamide Chemical compound C1=C(C=2OC=CC=2)ON=C1C(=O)NCCCN1C=CN=C1 PQXINDBPUDNMPE-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000003100 immobilizing effect Effects 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 210000003061 neural cell Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000004129 prosencephalon Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HXBKPYIEQLLNBK-UHFFFAOYSA-N 4-(4-octylphenyl)benzoic acid Chemical compound C1=CC(CCCCCCCC)=CC=C1C1=CC=C(C(O)=O)C=C1 HXBKPYIEQLLNBK-UHFFFAOYSA-N 0.000 description 3
- KFBPBWUZXBYJDG-UHFFFAOYSA-N 4-[(1,1,3,3-tetramethyl-2-oxoindene-5-carbonyl)amino]benzoic acid Chemical compound C=1C=C2C(C)(C)C(=O)C(C)(C)C2=CC=1C(=O)NC1=CC=C(C(O)=O)C=C1 KFBPBWUZXBYJDG-UHFFFAOYSA-N 0.000 description 3
- OQVLOWLEEHYBJH-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethynyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C#CC1=CC=C(C(O)=O)C=C1 OQVLOWLEEHYBJH-UHFFFAOYSA-N 0.000 description 3
- HSAOETBFVAWNRP-UHFFFAOYSA-N 4-[4-(2-butoxyethoxy)-5-methyl-1,3-thiazol-2-yl]-2-fluorobenzoic acid Chemical compound S1C(C)=C(OCCOCCCC)N=C1C1=CC=C(C(O)=O)C(F)=C1 HSAOETBFVAWNRP-UHFFFAOYSA-N 0.000 description 3
- VCQGNUWOMLYNNG-UHFFFAOYSA-N 4-[7-(1-adamantyl)-6-hydroxynaphthalen-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=C(O)C(=C2)C34CC5CC(CC(C5)C3)C4)C2=C1 VCQGNUWOMLYNNG-UHFFFAOYSA-N 0.000 description 3
- SZWKGOZKRMMLAJ-UHFFFAOYSA-N 4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(=O)NC1=CC=C(C(O)=O)C=C1 SZWKGOZKRMMLAJ-UHFFFAOYSA-N 0.000 description 3
- LDGIHZJOIQSHPB-UHFFFAOYSA-N CD437 Chemical compound C1C(C2)CC(C3)CC2CC13C1=CC(C2=CC3=CC=C(C=C3C=C2)C(=O)O)=CC=C1O LDGIHZJOIQSHPB-UHFFFAOYSA-N 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 3
- 102100037506 Paired box protein Pax-6 Human genes 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000001654 germ layer Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000001002 morphogenetic effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000001020 neural plate Anatomy 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000008672 reprogramming Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- FOUVTBKPJRMLPE-FMIVXFBMSA-N 4-[(e)-3-(3,5-ditert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(C(=O)\C=C\C=2C=CC(=CC=2)C(O)=O)=C1 FOUVTBKPJRMLPE-FMIVXFBMSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000001327 Förster resonance energy transfer Methods 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 description 2
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 238000013406 biomanufacturing process Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 229950003662 fenretinide Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000000813 microcontact printing Methods 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011222 transcriptome analysis Methods 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- NTSBZVCEIVPKBJ-UHFFFAOYSA-N 1-azakenpaullone Chemical compound C1C(=O)NC2=CC=CN=C2C2=C1C1=CC(Br)=CC=C1N2 NTSBZVCEIVPKBJ-UHFFFAOYSA-N 0.000 description 1
- OXPHUHSZLODPNL-UHFFFAOYSA-N 3,4-bis(1h-indol-7-yl)pyrrole-2,5-dione Chemical compound C=1C=CC=2C=CNC=2C=1C=1C(=O)NC(=O)C=1C1=CC=CC2=C1NC=C2 OXPHUHSZLODPNL-UHFFFAOYSA-N 0.000 description 1
- AANFHDFOMFRLLR-IBGZPJMESA-N 3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid Chemical compound O=C([C@@H](O)C=1C=C2C(C)(C)CCC(C2=CC=1)(C)C)NC1=CC=C(C(O)=O)C=C1F AANFHDFOMFRLLR-IBGZPJMESA-N 0.000 description 1
- AANFHDFOMFRLLR-UHFFFAOYSA-N 3-fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(O)C(=O)NC1=CC=C(C(O)=O)C=C1F AANFHDFOMFRLLR-UHFFFAOYSA-N 0.000 description 1
- FHCSBLWRGCOVPT-UHFFFAOYSA-N AZD2858 Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C(=O)NC=2C=NC=CC=2)C=C1 FHCSBLWRGCOVPT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 101710141544 Allatotropin-related peptide Proteins 0.000 description 1
- 102000010264 Axin Signaling Complex Human genes 0.000 description 1
- 108010077596 Axin Signaling Complex Proteins 0.000 description 1
- VUODRPPTYLBGFM-CMDGGOBGSA-N BMS-453 Chemical compound C12=CC(\C=C\C=3C=CC(=CC=3)C(O)=O)=CC=C2C(C)(C)CC=C1C1=CC=CC=C1 VUODRPPTYLBGFM-CMDGGOBGSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 102220480540 Glycogen synthase kinase-3 beta_R96A_mutation Human genes 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101100281008 Homo sapiens FGF2 gene Proteins 0.000 description 1
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 1
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 1
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- HUDSYNWJCPDHLL-CJLVFECKSA-N [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate Chemical compound CC(=O)O\N=C1\C(=Nc2ccccc12)c1c(O)[nH]c2cc(Br)ccc12 HUDSYNWJCPDHLL-CJLVFECKSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000032341 cell morphogenesis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011960 computer-aided design Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- DUDCYUDPBRJVLG-UHFFFAOYSA-N ethoxyethane methyl 2-methylprop-2-enoate Chemical compound CCOCC.COC(=O)C(C)=C DUDCYUDPBRJVLG-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 102000056097 human CTNNB1 Human genes 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 230000024764 neural tube development Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 102220198146 rs1057519886 Human genes 0.000 description 1
- 102200044883 rs121913228 Human genes 0.000 description 1
- 102220198042 rs121913407 Human genes 0.000 description 1
- 102200044888 rs121913412 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3675—Nerve tissue, e.g. brain, spinal cord, nerves, dura mater
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/434—Inhibitors, antagonists of enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2531/00—Microcarriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2535/00—Supports or coatings for cell culture characterised by topography
- C12N2535/10—Patterned coating
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
- C12N2537/10—Cross-linking
Definitions
- hPSCs Human pluripotent stem cells
- the brain and spinal cord develop from the neural tube, a hollow tube of polarized neuroepithelial cells (also termed neural stem cells).
- polarized neuroepithelial cells also termed neural stem cells.
- 2- and 3-D cultures of differentiating neuroepithelial cells can initiate organoid formation through spontaneous polarization of neural rosettes, which function like slices of the neural tube.
- Neural stem cell differentiation protocols have been previously disclosed as well as a micropatterned in vitro culture protocol for controlled formation of singular neural rosette structures.
- Such neural rosettes model a transverse slice of the developing neural tube, but their small size limits their use as a substrate for further bioengineering; for example, the diameter is too small to generate a significant microfluidic gradient of cell culture factors.
- there is tin ongoing need for improved methods and compositions for controlled induction of formation of larger rosette tissues that are more biomimetic of neural tube morphology and that facilitate further morphogenetic bioengineering using microfluidic platforms.
- Described herein are methods, compositions, and kits for making larger bioengineered neuroepithelial tissues and neuroepithelial tubes that are more biomimetic of neural tube morphology and facilitate further morphogenetic bioengineering using microfluidic platforms.
- an elliptical morphology e.g., major axis up to >1 mm and minor axis about 250-300 ⁇ m
- biomimetic elliptical neuroepithelial tissue having a singular rosette structure in vitro comprises the following steps: (a) seeding human pluripotent stem cells (hPSCs) in the presence of a Rho kinase inhibitor onto a micropatterned substrate that induces biomimetic neural morphogenesis of cells cultured thereon, wherein the micropatterned substrate comprises at least two cell- adhesive, circular regions connected by a cell-adhesive bridge; (b) culturing the seeded micropatterned substrate for a first culture period of about one to two days in the presence of a pluripotency maintenance base medium to obtain a first cell population, wherein the pluripotency maintenance base medium comprises a Rho kinase inhibitor; (c) culturing the micropatterned substrate thereof for a second period of about 2 to about 6 days under adherent conditions in a neural differentiation base medium, whereby a biomimetic elliptical neuroe
- the above methods further comprise overlaying the bioengineered neuroepithelial tissue obtained therein with a hydrogel layer, culturing the bioengineered neuroepithelial tissue for about 24 hours, whereby the tissue morphs into a bioengineered neuroepithelial tube and becomes encased in the hydrogel layer, and removing the hydrogel comprising the encased neuroepithelial tube from the micropatterned substrate, to obtain a bioengineered neuroepithelial tube.
- this disclosure provides is a microfluidics device comprising a. micropatemed substrate as described herein for obtaining an in vitro bioengineered neuroepithelial tissue.
- morphogen refers to a molecule or mixture of molecules that induces differentiation and/or proliferation of a cell such as a neural progenitor.
- the morphogen provides spatial information via a concentration gradient that can affect patterning of a differentiating neural tissue.
- a morphogen is a diffusible protein, cytokine, or growth factor.
- kits comprising one or more components useful for obtaining an in vitro biomimetic neuroepithelial tissue or a bioengineered neuroepithelial tube.
- Components of the kit can include one or more micropatterned substrates as described herein.
- the kit can also contain a chemically defined culture medium and one or more medium additives (e.g., growth factors, small molecule compounds, culture medium supplements).
- the kit can further contain progenitor cells useful for the seeding of the micropatterned substrate and instructions for cell seeding and culture.
- kits in some embodiments, it will be advantageous for a kit to comprise one or more micropatterned substrates as described herein and one or more agents (e.g., growth factors, small molecule agents, agents to create a morphogen gradient) useful to further differentiate the neuroepithelial tissue to contain various types of neurons.
- the kit can also comprise a microfluidics device or components thereof, for example, to deliver patterning agents to the bioengineered neuroepithelial tissue in a pre-determined manner.
- the kit further comprises a hydrogel suitable for use as an overlay on the biomimetic elliptical neuroepithelial tissue to obtain an encased bioengineered neuroepithelial tube according to methods of this disclosure.
- engineered in vitro bioengineered neuroepithelial tissue obtained by one of the methods disclosed herein, comprising a single rosete of polarized neuroepithelial cells and having microscale cellular organization similar to that of a transverse section of an in vivo developing human neural tube.
- composition comprising one or more micropatterned substrates that is capable of biomimetic neural morphogenesis of cells cultured thereon, wherein the micropatterned substrate comprises at least two circular, cell-adhesive microscale regions and connected by a cell-adhesive bridge.
- the present disclosure provides a method of producing a biomimetic elliptical neuroepithelial tissue having a singular rosette structure in vitro.
- the method includes: (a) seeding human pluripotent stem cells (hPSCs) in the presence of a Rho kinase inhibitor onto a micropatterned substrate that is capable of biomimetic neural morphogenesis of cells cultured thereon, wherein the micropatterned substrate comprises at least two circular bounded regions connected by a cell-adhesive bridge: (b) culturing the seeded cells of step (a) on the micropatterned substrate for a first culture period of about one to two days in the presence of a pluripotency maintenance medium to obtain a first cell aggregate, wherein the pluripotency maintenance medium comprises a Rho kinase inhibitor; and (c) culturing the cells obtained in step (b) for a second culture period of about 3 to about 6 days under adherent culture conditions in a neural differentiation base
- each of the at least two circular bounded regions has a diameter of about 100 ⁇ m to about 300 ⁇ m.
- the cell-adhesive bridge has a length of about 25 ⁇ m to about 125 ⁇ m, and has a width of about 10 ⁇ m to about 50 ⁇ m.
- tire cell-adhesive bridge has a length of about 50 ⁇ m to about 100 ⁇ m and has a width of about 2.5 ⁇ m.
- the hPSCs are seeded onto the micropatterned substrate at a density of between about 75 ⁇ 10 3 cells/cm 2 and about 2.5 ⁇ 10 3 cells/cm 2 . In one embodiment of the first particular aspect, the hPSCs are seeded onto the micropatterned substrate at a-density of about 165,000 cells/cm 2 . In one embodiment of the first particular aspect, the pluripotency maintenance medium is a chemically defined medium comprising DMEM/F-12, ascorbic acid, sodium bicarbonate, selenium, insulin, transferrin, FGF2, and TGF ⁇ 1.
- the pluripotency maintenance medium is E8 medium.
- the neural differentiation base medium is a chemically defined medium comprising DMEM/F-12, ascorbic acid, sodium bicarbonate, selenium, insulin, and transferrin.
- the neural differentiation base medium is E6 medium.
- the neural differentiation base medium further comprises one or more of an FGF with or without an activator of ⁇ -catenin pathway signaling.
- the FGF is FGF2, FGF8a, FGF8b, FGF8f, FGF 17, or FGF18.
- the activator of ⁇ -catenin pathway signaling is a GSK3 kinase inhibitor.
- the GSK3 kinase inhibitor is CHIR99021.
- the neural differentiation base medium further comprises about 100 ng/ml to about 200 ng/ml FGF8b and about 3 ⁇ M to about 9 ⁇ M CHIR99021.
- the second culture period is about 5 days.
- the method further comprises transiently exposing cells on the micropatterned substrate to an activator of Wnt/p-catemn signaling about 24-72 hours after plating onto the micropatterned substrate.
- the method further comprises about 24-72 hours after seeding cells onto the micropatterned substrate, exposing the seeded cells to RA and Sonic Hedgehog (SHH) or a SHH signaling agonist for about 1 to about 5 days, whereby the rosette structure comprises Olig2+ motor neurons progenitors (pMNs).
- SHH Sonic Hedgehog
- pMNs Olig2+ motor neurons progenitors
- the micropatterned substrate comprises a singular or plurality of polyethylene glycol (PEG) brashes or peptide- immobilizing PEG brashes arranged in a user-defined, bounded geometry.
- PEG polyethylene glycol
- the method further comprises overlaying the neuroepithelial tissue obtained in step (c) of the first particular aspect with a hydrogel layer; and culturing the neuroepithelial tissue comprising the hydrogel layer for about 24 hours, whereby the tissue morphs into a bioengineered neuroepithelial tube and becomes encased in the hydrogel layer.
- the method further comprises removing the hydrogel comprising the encased bioengineered neuroepithelial tube from the micropatterned substrate. In one embodiment of the first particular aspect, the method further comprises fixing and sectioning the removed hydrogel for analysis. In one embodiment, the hydrogel is Matrigel.
- the present disclosure provides an in vitro bioengineered neuroepithelial tissue obtained by the method of the first particular aspect, the tissue comprises a single rosette of polarized neuroepithelial cells and has microscale cellular organization similar to that of a transverse section of an in vivo developing human neural tube.
- the present disclosure provides an in vitro bioengineered neuroepithelial tube obtained by the method of the first particular aspect or any embodiments thereof. The tube comprises a single rosette of polarized neuroepithelium and has microscale cellular organization similar to that of an in vivo developing human neural tube.
- the present disclosure provides a composition that includes one or more micropatterned substrates that is capable of instructing biomimetic neural morphogenesis of cells cultured thereon.
- the one or more micropatterned substrates comprises at least two circular, cell-adhesive microscale regions connected by a cell-adhesive bridge.
- kits including the composition of the fourth particular aspect and that further includes one or more of a vial of progenitor cells, a pluripotency base medium, a neural differentiation base medium, a microfluidic device, and reagents to prepare a morphogen gradient.
- the present disclosure provides a method of producing a bioengineered neuroepithelial tube in vitro.
- the method includes: (a) seeding human pluripotent stem cells (hPSCs) in the presence of a Rho kinase inhibitor onto a micropatterned substrate that is capable of biomimetic neural morphogenesis of cells cultured thereon, wherein the micropatterned substrate comprises at least two circular bounded regions and connected by a cell-adhesive bridge; (b) culturing the seeded cells of step (a) on the micropatterned substrate for a first culture period of about one to two days in the presence of a pluripotency maintenance medium to obtain a first cell aggregate, wherein the pluripotency maintenance medium comprises a Rho kinase inhibitor; (c) culturing the cells of step (b) tor a second culture period of about 3 to about 6 days under adherent culture conditions in a neural differentiation base medium, whereby a bioengineered neuroepithelial
- the present disclosure provides an in vitro bioengineered neuroepithelial tube obtained by the method of the fifth particular aspect.
- the tube comprises a single rosette of polarized neuroepithelium and has microscale cellular organization similar to that of an in vivo developing human neural tube.
- FIG. 1 shows computer-aided designs of features presented on polydimethylsiloxane (PDMS) stamps used for microcontact printing of custom culture substrates: (top) a paired circle micropattern configuration without bridges and (bottom) a micropattern comprising pairs of circles, alternatively termed “nodes,” connected thereto by a bridge. Circle diameters vary between 150-250 ⁇ m with edge-to-edge separation of varying distances. Bridge thickness is 25 microns.
- PDMS polydimethylsiloxane
- the middle graph quantifies the percentage of micropatterned tissues that fused between pairs (graph bars are D3, D4, D5, and D6 from left to right for each edge-edge distance).
- the bottom graph depicts the percentage of micropatterned tissue pairs that fused and formed a single rosette polarization out of all fused micropatterned tissue pairs (graph bars are D3, D4, D5, and D6 from left to right for each edge- edge distance).
- N 56 technical replicates per experimental group.
- Middle graph quantifies the percentage of micropatterned tissues that fused between pairs (graph bars are D3, D4, D5, and D6 from left to right for each edge-edge distance).
- the bottom graph depicts the percentage of micropatterned tissue pairs that fused and formed a single rosette polarization out of all fused micropatterned tissue pairs (graph bars are D3, D4, D5, and D6 from left to right for each edge- edge distance).
- N 56 technical replicates per experimental group.
- the top middle image montage shows representative images of micropatterned neuroepithelial tissues across days in culture at edge-to-edge separations of 50 ⁇ m with bridges.
- the top graph quantifies the percentage of micropatterned tissues that fused across entire rows at edge-to-edge separations of 25, 50, 75, 100, and 125 ⁇ m with bridges (graph bars are D3, D4, D5, and D6 from left to right for each edge-edge distance),
- the bottom graph depicts the percentage of micropatterned tissue rows that fused and formed a single rosette polarization out of all fused micropatterned tissue rows (graph bars are D3, D4, D5, and D6 from left to right for each edge-edge distance).
- N 4 technical replicates per experimental group.
- FIG. 5 shows that micropatterned neural tissue fusions span an entire row on micropatterned arrays by Day 5.
- N-cadherin dashed arrows
- Pax6 solid arrows.
- FIG. 6 illustrates that (top) circular micropatems separated by 50 um edge-to- edge and with bridges enable formation of a contiguous, fused tissue with a single N-cadherin + rosette polarization across the entire micropatterned row (middle) that starts becoming a three dimensional tube with apical N-cadherin (dashed arrows) expression over 5 days in culture as shown with images from a confocal Z-stack (bottom).
- N-cadherin dashed arrows
- Laminin solid arrows
- DAPI compound arrows.
- FIG. 7 shows (top) the experimental protocol for (middle-top) deriving micropatterned forebrain neuroepithelial tubes and (middle -bottom) overlaying wdth Matrigel hydrogel on Day 5 for (bottom) 24 hrs,
- NECs neuroepithelial cells
- 2D two-dimensional
- 3D three-dimensional
- This invention provides methods for controlling neural rosette formation, thereby producing neuroepithelial tissues having an elliptical morphology with tunable aspect ratios.
- These elliptical neuroepithelial tissues mimic primary neurulation routinely and reproducibly form 3-D neuroepithelial tubes that exhibit structural characteristics more similar to the developing neural tube than those obtainable by previously described neural organoid derivation methods.
- hPSC human pluripotent stem cell
- hESCs human embryonic stem cells
- hiPSCs human induced pluripotent stem cells
- iPS cells refer to cells that are substantially genetically identical to their respective differentiated somatic cell of origin and display characteristics similar to higher potency cells, such as ES cells, as described herein.
- the cells can be obtained by reprogramming non-pluripotent (e.g., multipotent or somatic) cells.
- non-pluripotent e.g., multipotent or somatic cells.
- pluripotency means a cell's ability to differentiate into cells of all three germ layers.
- neural stem cell refers to a multipotent stem cell that is PAX6 + /Sox2 + and is capable of differentiating into neurons or glia of the CNS or peripheral nervous system (PNS).
- PNS peripheral nervous system
- neuroepithelial cells refer to neural stem cells that are polarized epithelial cells exhibiting apico-basal polarity within neural rosette structures.
- NMPs neurotrophic factor-derived progenitors
- elliptical means having an oval shape or shape like an ellipse, which is an elongated circle, stretched into an oval.
- An elliptical shape deviates from an ideal circle such that distance from the center of the shape to the edge of the shape varies (unlike in a circle where the distance from tbe center of the circle to any point along the edge remains constant).
- the terms “oval,” “elliptical” or “generally elliptical” are used interchangeably herein, and it is not considered essential that a substrate, tissue, or other material of this disclosure have a precise elliptical configuration.
- neural rosette refers to a neuroepithelial tube analog comprising neuroepithelial cells (NECs) that forms when human pluripotent stem cells are neurally differentiated in two-dimensional (2D) and three-dimensional (3D) culture.
- NECs neuroepithelial cells
- Neural rosette morphology can be elucidated by apical N-cadherin localization along constituent cell membranes with apico-basal polarity.
- a “biological molecule” or “biomolecule” as used in the context of this invention refers to a molecule that is substantially of biological origin. Such molecules can include non-naturally occurring components that mimic a naturally occurring component, e.g., a non-naturally occurring amino acid.
- tissue material that has been created or modified by the hand of man (e.g., formed in vitro using man-made materials) or is derived using such material (e.g., a device or composition comprising the engineered material).
- organoid refers to a tissue-like structure (i.e., exhibiting structural properties of a particular tissue type) that resembles a developing organ and is assembled in vitro by the separate addition and self-organization of cell types including, but not limited to, pluripotent stem cells or neural stem cells. See, e.g., Lancaster and Knooff, Science 345(6194): 1247125 (2014).
- polypeptide “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues.
- the terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.
- cell culture medium as used herein (also referred to herein as a “’culture medium” or “medium” or “culture media”) is a medium for culturing cells containing nutrients that maintain cell viability and support proliferation.
- culture medium or “chemically defined medium,” as used herein, means that the chemical structure and quantity of each medium ingredient is specifically known or identifiable, and can be controlled individually. As such, a culture medium is not chemically defined if (1) the chemical and structural identity of all medium ingredients is not known, (2) the medium contains unknown quantities of any ingredients, or (3) both.
- a medium consisting essentially of means a medium that contains the specified ingredients and those that do not materially affect its basic characteristics.
- “Supplemented,” as used herein, refers to a composition, e.g., a medium comprising a supplemented component (e.g., retinoic acid or fibroblast growth factor (FGF)).
- a medium “further supplemented” with retinoic acid (RA) or a FGF refers to the medium comprising RA or FGF, but not to the act of introducing the RA or FGF to the medium.
- “effective amount” means an amount of an agent sufficient to evoke a specified cellular effect according to this invention.
- xenogen free and “xeno-free” are used interchangeably and refer to a material that is free of or substantially free of xenogeneic material or undefined components that are derived from a non-human source.
- Neuronal differentiation base medium refers to a medium capable of promoting and supporting differentiation of human pluripotent stem cells towards a neural lineage, e.g., towards neuroectoderm and neuroepithelium.
- a neural differentiation base medium can include, but is not limited to E6 medium, as described herein and in U.S. Patent Publication No. 2014/0134732, the disclosure of which is incorporated by reference in its entirety.
- the terms “purified” or “enriched” cell populations are used interchangeably herein, and refer to cell populations, ex vivo, that contain a higher proportion of a specified cell type or cells having a specified characteristic than are found in vivo (e.g., in a tissue).
- serum-free means that a medium does not contain serum or serum replacement, or that it contains essentially no serum or serum replacement.
- an essentially serum-free medium can contain less than about 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2% or 0.1% serum, wherein competent culturing capacity of the medium is still observed.
- substantially free of means that a culture medium or other composition or solution is free or nearly free of a particular component.
- substantially free of putrescine means no putrescine is added to a cell culture medium above and beyond any putrescine present in the base medium, e.g., DMEM/F12.
- substantially free of putrescine means a final putrescine concentration less than or equal to 0.08 mg/L.
- viability means the state of being without substantial cell death. Pluripotent cells that are viable attach to the surface and do not stain with the dye propidium iodide absent membrane disruption. Short term viability relates to the first 2.4 hours after plating the cells in culture. Typically, the cells do not proliferate in that time.
- cross-linking or “cross-linked” refers to a bond that links one polymer chain to another to form, inter alia, a hydrogel. These links can be covalent bonds or ionic bonds.
- the terms “about” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Typical, exemplary degrees of error are within 10%, and preferably within 5% of a given value or range of values. Alternatively, and particularly in biological systems, the terms “about” and “approximately” can mean values that are within an order of magnitude, preferably wi thin 5- fold and more preferably within 2-fold of a particular value. Numerical quantities set forth herein are approximate unless stated otherwise, meaning that the term “about” or “approximately” can be inferred when not expressly stated.
- ordinal terms such as “first,” “second,” “third,” etc., in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed. Ordinal terms are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term), to distinguish the claim elements.
- the invention set forth herein discloses a micropattern design comprising multiple circular regions connected by a cell-adhesive bridge that can induce formation of neuroepithelial tissues with a non-circuiar morphology and a single polarized rosette structure that spans the entire tissue. Furthermore, as shown in FIG. 3 and 4, creating a micropattern with a connected series of multiple circles permits formation of a singular neuroepithelial rosette tissue having substantially elliptical morphology (e.g., major axis up to >1 mm and minor axis about 250-300 ⁇ m) that can be extended indefinitely.
- substantially elliptical morphology e.g., major axis up to >1 mm and minor axis about 250-300 ⁇ m
- an elliptical morphology e.g., major axis up to >1 mm and minor axis about 250-300 ⁇ m
- biomimetic elliptical neuroepithelial tissue refers to an elongated aggregate of cells or a tissue containing a singular neural rosette structure produced on micropatterned substrates of this disclosure, and having structural similarity to tissues found in nature, namely the anatomic structure and cytoarchitecture of the embryonic neural tube or a transverse section thereof (FIG. 3).
- Bioengineered neuroepithelial tubes produced therefrom are in vitro-derived (e.g., engineered) cell aggregates that, as shown in FIG. 6 and 8, mimic polarized 3-D neural tube cytoarchitecture, with polarized NSCs displaying apical N-cadherin expression and basal extracellular matrix protein deposition along the entire axial of the 3D cylindrical tissue aggregate.
- biomimetic elliptical neuroepithelial tissue having a singular rosette structure in vitro comprises the following steps: seeding human pluripotent stem cells (hPSCs) in the presence of a Rho kinase inhibitor onto a micropatterned substrate that is capable of biomimetic neural morphogenesis of cells cultured thereon, wherein the micropatterned substrate comprises at least two circular bounded regions connected by a cell-adhesive bridge; culturing the seeded micropatterned substrate for a first culture period of about one to two days in the presence of a pluripotency maintenance base medium to obtain a first cell population, wherein the pluripotency maintenance base medium comprises a Rho kinase inhibitor; and culturing the cultured micropatterned substrate thereof for a second culture period of about 2 to about 6 days under adherent culture conditions in a neural differentiation base medium, whereby a biomimetic elliptical neuroepithelial tissue
- the micropatterned substrate comprises at least two circular bounded regions connected by a cell-adhesive bridge, and in some embodiments, comprises a series of interconnected circular bounded regions. While the number of circular bounded regions should be at least two, the number of interconnected circular bounded regions in the series is limited only by the ability to prepare the predetermined arrangement on a substrate (e.g., limited by dimensions of the micropatterned substrate itself).
- the micropatterned substrates can be produced by simple microprinting of alkanethiols without grafted polymer brushes and can be used in the methods disclosed herein. See, Ashton et al., 2007, Stem Cells 25: 2928-2935, the disclosure of which is expressly incorporated by reference herein in its entirety.
- the micropatterned substrate comprises an engineered, predetermined (i.e., user-defined) arrangement of one or more surface-grafted poly(ethylene glycol) (“PEG”) brushes, which robustly resist protein adsorption and thereby ceil adhesion.
- PEG poly(ethylene glycol)
- a micropatterned substrate comprises a user-defined arrangement of one or more PEG brushes grafted onto a solid support (e.g., tissue culture polystyrene, glass slide, glass, or silica substrates).
- a solid support e.g., tissue culture polystyrene, glass slide, glass, or silica substrates.
- Micropatterned regions resistant to cell attachment can comprise a singular or a plurality of surface-grafted PEG brushes lacking any cell attachment peptides or other moieties that promote cell attachment.
- Micropattemed regions that promote adherence of cells cultured thereon can comprise a singular or a plurality of PEG blushes having a peptide-immobilizing moiety.
- the arrangement of a singular or a plurality of peptide- immobilizing PEG brashes provides a user-defined, tunable substrate that can control cell adhesion and thereby the resulting morphology of adherent cell aggregates of tissues.
- PEG brushes can be chemically modified to enable in situ conjugation of peptides, whose sequences are derived from extracellular matrix (“ECM”) proteins.
- ECM extracellular matrix
- a micropatterned substrate can comprise an arrangement of PEG brushes comprising peptides having one or more RGD (Arg-Gly-Asp) sequence motifs, which are also known as mtegrin binding motifs that promote cell adhesion.
- a RGD sequence motif corresponds to a cell attachment site of a large number of adhesive ECM and cell surface proteins.
- RGD sequences are common in integrin-binding adhesion proteins such as fibronectin, collagen, and laminin. The integrin-binding activity of such adhesion proteins can be mimicked by short synthetic peptides containing the RGD sequence. Accordingly, to promote adherence of cells to particular regions of a micropatterned substrate, those regions can comprise one or more PEG brushes conjugated to RGD-containing peptides. For regions that are resistant to cell attachment, PEG brashes lacking any cell adhesion molecules (e.g., cell tethering moiety) are preferably used.
- a micropatterned substrate is obtained according to the synthesis protocols described by Knight et al., 2015, Chem. Commun. 51 : 5238-52.41, which is incorporated by reference herein as if set forth in its entirety.
- a micropatterned substrate can be an azide-functionalized polyethylene glycol) methacrylate (PEGMA)-grafted substrate that is capable of undergoing a 1,3-dipolar cycloaddition “click” reaction with peptides conjugated to high strain molecules such as dibenzocyclooctyne (DBCO).
- PEGMA polyethylene glycol methacrylate
- PEG brushes present dual orthogonal chemistries (i.e., azido and acetylene groups) for ligand (e.g., peptide) immobilization via versatile copper-free click reactions, which are useful for in situ surface modifications during cell culture and thereby spatiotemporal control of adherent tissue morphologies.
- a micropatterned substrate comprises one or more PEG brushes or polyethylene glycol) methacrylate (PEGMA)-azide brushes throughout except for an array of interconnected circles having a diameter of about 100 ⁇ m, 200 ⁇ m, 250 ⁇ m, 300 ⁇ m, or more, where the circles are connected by cell-adhesive bridges.
- PEG brushes or polyethylene glycol) methacrylate (PEGMA)-azide brushes throughout except for an array of interconnected circles having a diameter of about 100 ⁇ m, 200 ⁇ m, 250 ⁇ m, 300 ⁇ m, or more, where the circles are connected by cell-adhesive bridges.
- PEG brushes or polyethylene glycol) methacrylate (PEGMA)-azide brushes throughout except for an array of interconnected circles having a diameter of about 100 ⁇ m, 200 ⁇ m, 250 ⁇ m, 300 ⁇ m, or more, where the circles are connected by cell-adhesive bridges.
- the cells when coated with extracellular matrix
- the micropatterned substrates provided herein can chemically modified to display a plurality of cell adhesion peptides arranged according to user-defined, tunable spatial parameters.
- User-defined parameters include spacing, diameter (also sometimes referred to herein as “width”), height (also sometimes referred to herein as “length”), and number of cell adhesion peptides per unit of surface area (also referred to herein as “cell adhesion peptide surface area density”).
- micropatterned substrates comprising regions that promote adherence of cells cultured thereon, where these regions are engineered (i.e., configured) to have a bounded geometry to promote differentiation and morphogenesis of neuromesodermal progenitors (NMPs), neural stem cells (NSCs), or human pluripotent stem cells (hPSCs) cultured on or recruited to the matrix.
- NMPs neuromesodermal progenitors
- NSCs neural stem cells
- hPSCs human pluripotent stem cells
- bounded geometries of a micropatterned substrate that comprises at least two circular bounded regions and connected by a cell-adhesive bridge can be used to control the macroscale structuring of neural tissue during cell differentiation and morphogenesis of hPSCs, NSCs, or NMPs on the culture substrate to form a singular neuroepithelial rosette tissue having elliptical morphology.
- the bounded geometric shape can be various two-dimensional (2-D) shapes (e.g., regular or irregular) having dimensions defined by the shape (e.g., diameter, width, length and the like), it is advantageous for the micropatterned substrate to comprise a predetermined two- dimensional pattern of at least two circular regions of varying dimensions (e.g., 36 ⁇ m, 100 ⁇ m, 490 ⁇ m, 4.8 mm, and 12.6 mm in diameter; typically about 150-300 ⁇ m) that are separated from each other by a predetermined distance and are connected by a bridge of the same cell- adhesive material.
- 2-D two-dimensional
- the bounded geometric shape of each of the at least two circles has a diameter of about 100 ⁇ m, 150 ⁇ m, 180 ⁇ m, 200 ⁇ m, about 300 ⁇ m, or about 400 ⁇ m (e.g., about 100, 150, 200, 250, 300, 350, 400 ⁇ m, inclusive).
- a circle or other shape having a diameter of less than 100 ⁇ m and, in some embodiments, as low as 50 ⁇ m (e.g., 50, 60, 70, 80, 90, or 100 ⁇ m, inclusive) can be used, however proliferating cells grown on smaller micropatterned surfaces (i.e., having a diameter less than 100 ⁇ m) tend to lift off the surface as an aggregate or ball of cells. Accordingly, practical constraints can set a lower limit on micropaterned surface dimensions.
- the regions are preferably spaced apart at distance of about 25 ⁇ m to about 125 ⁇ m (e.g., about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125 ⁇ m, inclusive), and more preferably at a distance of about 50 ⁇ m to about 100 ⁇ m.
- the length of the cell-adhesive bridge that connects at least two circular bounded regions is preferably about 10 ⁇ m to about.
- 100 ⁇ m (e.g., about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 ⁇ m, inclusive), and more preferably about 20 ⁇ m to about 60 ⁇ m.
- the micropatterned substrate comprises, for example, a predetermined two-dimensional pattern of multiple interconnected circles in a series, where each circle has approximately the same diameter and each of any two neighboring circles shares approximately the same edge-to-edge spacing. While the diameters of each circle and spacing between circle can be varied, the inventors determined that a particular micropattern having an edge-to-edge spacing between interconnected circles of about 25 ⁇ m to about 125 ⁇ m, and more preferably about 25 ⁇ m to about 50 ⁇ m (FIG. 3 and 4) is an advantageous configuration. [00081] With respect to cell-adhesive bridge widths connecting at least, two circular bounded regions, bridge width is advantageously about 10 ⁇ m to about 100 ⁇ m, and more specifically 25 ⁇ m.
- micropatterned substrates are produced by manually depositing peptide- immobilizing PEG brushes and cell adhesion peptides onto a solid support.
- micropatterned substrates are produced using automated (e.g., robotic) techniques, microcontact printing, microfluidic etching, or deposition of various materials.
- photolithography-based microfabrication techniques can be used.
- photolithography-based microfabrication techniques can be used to produce templates or molds for micrometer-level patterning of a cell adhesion-resistant substance (e.g., a nonadherent agar) onto a substrate, e.g., a glass slide, a glass coverslip, or an elastomeric polymer (e.g., polydimethylsiloxane (PDMS)) coated with a cell adhesive material.
- a cell adhesion-resistant substance e.g., a nonadherent agar
- a substrate e.g., a glass slide, a glass coverslip, or an elastomeric polymer (e.g., polydimethylsiloxane (PDMS)) coated with a cell adhesive material.
- PDMS polydimethylsiloxane
- micropatterned substrates disclosed herein can be used in any culture system including static (e.g., tissue culture plates) and fluid flow reactor systems (e.g., microfluidic devices). Such microfluidic devices are useful for rapid screening of agents where small flow rates and small reagent amounts are required. Microfluidic devices are also useful for in vitro exposure of a micropatterned substrate to one or more gradients of transcription factors or other factors (e.g., agents to create a morphogen gradient for morphogenetic patterning of neural tissue) capable of directing or influencing neural differentiation.
- static e.g., tissue culture plates
- fluid flow reactor systems e.g., microfluidic devices.
- microfluidic devices are useful for rapid screening of agents where small flow rates and small reagent amounts are required.
- Microfluidic devices are also useful for in vitro exposure of a micropatterned substrate to one or more gradients of transcription factors or other factors (e.g., agents to create a morphogen gradient for morphogenetic patterning of neural tissue) capable of
- this disclosure provides is a microfluidics device comprising a micropatterned substrate as described herein for obtaining an in vitro bioengineered neuroepithelial tissue.
- morphogen refers to a molecule or mixture of molecules that induces differentiation and/or proliferation of a cell such as a neural progenitor.
- the morphogen provides spatial information via a concentration gradient that can affect patterning of a differentiating neural tissue.
- a morphogen is a diffusible protein, cytokine, or growth factor.
- the resultant bioengineered neuroepithelial tissue can have nanoscale or microscale cellular organi zation similar to that of the corresponding in vivo developing organ.
- microscale cellular organization means that structural organization of cellular components (also known as “cytoarchitecture”) of a biomimetic 3D organoid is similar to a corresponding in vivo tissue at the microscale level, meaning on the order of sizes of less than 1000 ⁇ m, and more preferably less than 100 ⁇ m.
- progenitor cells can be used to seed the micropatterned substrate.
- PSCs pluripotent stem cells
- ESCs embryonic stem cells
- iPSCs induced pluripotent stem cells
- suitable progenitor cells are those able to form the polarized neural rosette structures (e.g., polarized staining of laminin and N-cadherin), including, but not limited to, hPSCs, neural stem cells (NSCs), or neuromesodermal progenitors (NMPs), among others.
- NMPs neuromesodermal progenitors
- biomimetic elliptical neuroepithelial tissue detaches from the micropatterned substrate as a three-dimensional structure encapsulated in the hydrogel.
- Hydrogel-encased bioengineered neuroepithelial tubes are useful for a variety of applications including, for example, bioengineering neural organoids having a 3-D structure analogous to the developing in vivo neural tube.
- Hydrogel-encased bioengineered neuroepithelial tubes are amenable to extended bioreactor culture or for further development and analysis including, without limitation, fixation, sectioning, immunohistochemistry (see FIG. 8), imaging, and in situ hybridization.
- the overlaying method comprises overlaying a biomimetic elliptical neuroepithelial tissue obtained according to methods of this disclosure with a hydrogel layer; culturing the tissue comprising the overlaid hydrogel layer for about 20-52 hours (e.g., about 20, 22, 24, 26, 28, 48, 50 or 52 hours), whereby the biomimetic elliptical neuroepithelial tissue becomes encased in the hydrogel layer to yield stable bioengineered neuroepithelial tubes.
- the hydrogel comprising the encased bioengineered neuroepithelial tube is removed from the micropatterned substrate for subsequent use or analysis. While this disclosure exemplifies using Matrigel for the hydrogel overlay, it will be understood any flexible hydrogel can be used including, without limitation, commercially available chemically defined alternatives to Matrigel substrates.
- a hydrogel containing the lifted bioengineered neuroepithelial tubes can be fixed in formalin or paraformaldehyde for sectioning using routine methods. If necessary, tissues can be cleared to make transparent and more amenable to imaging using light-based microscopy. In particular, light-sheet imaging and scanning electron microscopy (SEM) is useful to detect and analyze polarization within the bioengineered neuroepithelial tubes.
- SEM scanning electron microscopy
- confocal or light-sheet microscopy can reveal the distribution of cell types throughout a bioengineered neuroepithelial tube produced according to the methods of the invention.
- a three-dimensional assembly of images obtained by confocal or light-sheet microscopy is used to analyze the distribution and organization of various cells and structures therein.
- neural stem cells for use in the method provided herein are obtained by directed differentiation of human pluripotent stem cells (hPSCs).
- Suitable pluripotent cells for use herein include human embryonic stem cells (hESCs) and human iPSCs. These cells express Oct-4, S SEA-3, SSEA-4, TRA-1-60 and TRA-1-81, and appear as compact colonies having a high nucleus to cytoplasm ratio and prominent nucleolus.
- ESCs are commercially available from sources such as WiCell Research Institute (Madison, Wis.).
- induced pluripotent stem cells or “iPS cells” mean a pluripotent cell or population of pluripotent cells that can vary with respect to their differentiated somatic cell of origin, that can vary with respect to a specific set of potency-determining factors and that can vary with respect to culture conditions used to isolate them, but nonetheless are substantially genetically identical to their respective differentiated somatic cell of origin and display characteristics similar to higher potency cells, such as ESCs, as described herein. See, e.g., Yu et al., 2007, Science 318: 1917-1920, the disclosure of which is incorporated herein by reference in its entirety.
- Induced pluripotent stem cells exhibit morphological properties (e.g., round shape, large nucleoli and scant cytoplasm) and growth properties (e.g., doubling time of about seventeen to eighteen hours) akin to ESCs.
- iPS cells express pluripotent cell-specific markers (e.g., Oct-4, SSEA-3, S SEA-4, Tra-1-60 or Tra-1-81, but not SSEA-1).
- Induced pluripotent stem cells are not directly derived from embryos.
- the starting cell type for producing iPS cells is a non-pluripotent cell, such as a multipotent cell or terminally differentiated cell, such as somatic cells obtained from a post-natal individual.
- Human iPS cells can be used according to a method described herein to obtain primitive macrophages and microglial cells having the genetic complement of a particular human subject. For example, it can be advantageous to obtain biomimetic elliptical neuroepithelial tissues that exhibit one or more specific phenotypes associated with or resulting from a particular disease or disorder of the particular mammalian subject.
- iPS cells are obtained by reprogramming a somatic cell of a particular human subject according to methods known in the art. See, for example, Yu et al., 2009, Science 324:797-801; Chen et al., 2011, Nat.
- hPSCs Prior to seeding, hPSCs (e.g. , hESCs or hiPSCs), can be cultured in the absence of a feeder layer (e.g., a fibroblast layer) on a substrate suitable for proliferation of hPSCs, e.g. , MATRIGELTM, vitronectin, a vitronectin fragment, or a vitronectin peptide, or Synthemax®.
- hPSCs are passaged at least once to at least about 5 times in the absence of a feeder layer.
- Suitable culture media for passaging and maintenance of hPSCs include, but are not limited to, mTeSR® and E8TM media, available from Thermal Fisher/Life Technologies Inc.
- hPSCs are maintained and passaged under xeno-free conditions, where the cell culture medium is a defined medium such as E8 or mTeSR, but the cells are maintained on a completely defined, xeno-free substrate such as vitronectin or Synthemax® (or another type-of self-coating substrate).
- hPSCs are maintained and passaged in E8 medium on vitronectin, a vitronectin fragment, or a vitronectin peptide or a self-coating substrate such as Synthemax®.
- pluripotent stem cells that have been cultured in an adherent monolayer in a cell culture plate are subcultured onto a micropatterned surface and then cultured for a first culture period of about one (1) to two (2) days in defined pluripotency maintenance media followed by a second culture period of three (3) days to about six (6) days in a defined culture medium that supports differentiation of human pluripotent stem cells into neural stem cells, whereby PAX6-positive neural stem cells are obtained.
- hPSCs can be cultured in differentiation media suitable to differentiate the cells into an organoid.
- Suitable culture medium conditions are known in the art for differentiating hPSCs or other progenitor cells into organoid tissue in vitro.
- the culture medium is sufficient to promote self-organization and spontaneous morphogenesis of hPSCs into engineered neuroepithelial tube organoids in vitro.
- Suitable media include, for example, a neural differentiation medium.
- the cell-seeded hydrogels are cultured for a sufficient time to form the 3D organoid structure, for example, at least 4 days, at least 6 days, at least 8 days, or at least 16 days in culture.
- Neuronal differentiation medium refers to a medium capable of promoting and supporting differentiation of human pluripotent stem cells towards a neural lineage, e.g., towards neuroectoderm and neuroepithelium.
- a neural differentiation base medium can include, but is not limited to E6 medium, as described herein and in U.S. Patent Publication No. 2014/0134732, which is incorporated by reference herein in its entirety.
- the neural differentiation medium to be used in the neural differentiation method is “E4” medium, which consists essentially of a base medium (e.g., DMEM/F12 or a similar base medium as described herein) containing water, salts, amino acids, vitamins, a carbon source, and a buffering agent, plus selenium and insulin.
- the neural differentiation medium can also include ascorbate (said medium referred to herein as an “E5” medium).
- the neural differentiation medium to be used in the neural differentiation method is “E6” medium, which consists essentially of a carbonate-buffered E5 medium plus transferrin.
- E6 culture medium and “E6” are used interchangeably and refer to a chemically defined culture medium comprising or consisting essentially of DF3S supplemented to further comprise insulin (20 pg/mL) and/or transferrin (10.67 ng/mL).
- the medium can be prepared based on the formula in Chen et al., 2011, Nature Methods. 5(4), 424-429, which is incorporated by reference herein in its entirety. Similar medium is available from Thermal Fisher/Life Technologies Inc. as Essential 6, or from Stem Cell Technologies as TeSR-E6.
- E8 culture medium and “E8” are used interchangeably and refer to a chemically defined culture medium comprising or consisting essentially of DF3S supplemented by the addition of insulin (20 ⁇ g/mL), transferrin (10.67 ng/mL), human FGF2 (100 ng/mL), and human TGF ⁇ 1 (Transforming Growth Factor Beta 1) (1 ,75 ng/mL).
- the medium can be prepared based on the formula in Chen et al., 2011, Id.
- the medium is also available from Thermal Fisher/Life Technologies Inc. as Essential 8, or from Stem Cell Technologies as TeSR-E8.
- useful medium includes at least the same components as a neural differentiation medium mentioned above, but wherein the medium is substantially free of: a TGFP superfamily agonist (e.g., Nodal); an albumin, and at least one of putrescine and progesterone.
- a fibroblast growth factor e.g., FGF2
- FGF2 fibroblast growth factor
- the medium does not include a fibroblast growth factor.
- a retinoic acid receptor agonist is also included to facilitate neural differentiation into certain neuronal lineages depending on the concentration of retinoid used.
- retinoids and retinoid analogs include without limitation All-Trans Retinoic Acid (ATRA), Retinol Acetate, EC23 (4-[2-(5,6,7,8-Tetrahydro-5,5,8,8-te-tramethyl-2-naphthalenyl)ethynyl)-benzoic acid; CAS No: 104561-41-3), BMS453 (4-[(lE)-2-(5,6-Dihydro-5,5-dimethyi-8-phenyl-2- naphthalenyl)ethenyl] -benzoic acid; CAS No: 166977-43-10), Fenretinide (N-(4- Hydroxyphenyl)retinamide; CAS No: 65646-68-6), AM580 (4-[(5,6,7,8-Tetrahydro-5,5,8,8- tetramethyl-2-naphthalenyl)
- ATRA All-Trans Retinoic Acid
- EC23
- exemplary retinoic receptor agonists that could be used include AC261066 (4-[4-(2- Butoxyethoxy-)-5-methyl-2-thiazolyl]-2-fluorobenzoic acid; CAS No: 870773-76-5), AC55649 (4'-Octyl-[1,1'-biphenyl]-4-carboxylic acid; CAS No: 59662-49-6), Adapalene (6- (4“Methoxy-3-tricycio[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid; CAS No: 106685-40-9), AM80 (4-[[(5,6,7,8-Tetahydro-5,5,8,8-tetramethyl-2- naphthalenyl)amino] carbonyl] benzoic acid; CAS No: 94497-51-5), BMS753 (4-[[(2,3- Dihydro-1,1,3,3-tetramethyl-2-
- the concentration of the retinoic acid receptor agonist is about 0.1 ⁇ M to about 1.0 ⁇ M.
- a suitable concentration of retinoic acid receptor agonist ranges from about 0.1 ⁇ M to about 20 ⁇ M, e.g., about 0.2 ⁇ M, 0.3 ⁇ M, 0.5 ⁇ M, 1.0 ⁇ M, 2.5 ⁇ M, 3.0 ⁇ M, 3.5 ⁇ M, 4.0 ⁇ M, 5 ⁇ M, 7 ⁇ M, 10 ⁇ M, 12 ⁇ M, 15 ⁇ M, 17 ⁇ M or another concentration of ATRA from about 0.1 ⁇ M, to about 20 ⁇ M.
- the concentration of ATRA is about 3.0 ⁇ M.
- Suitable progenitor cells and culture conditions are contemplated that are able to form engineered cardiac tubes or gut epithelial tubes.
- cardiac progenitors or gut epithelial progenitor cells can be seeded onto micropaterned substrates and overlain with a supported hydrogel as described above.
- the resulting bioengineered neuroepithelial tubes made by the methods of this invention have microscale cellular organization similar to that of the corresponding in vivo developing organ.
- the biomimetic organoids have a single contiguous, polarized neural rosette structure (e.g., as demonstrated by laminin and N-cadherin polarized staining within the neuroepithelial tube) extending, in some embodiments, along 75% of the organoid's length.
- the contiguous, polarized neural rosette structure extends at least 75%, 80%, 90%, or 99% of the organoid's length.
- polarized refers to cells having bipolar (or bipolar or greater) morphology in which certain cellular components distributed unevenly between the two (e.g., apical and basal poles) or more poles of a cell.
- a polarized cell is a neuroepithelial cell exhibiting apico-basal polarity with respect to expression of N-cadherin.
- N-cadherin foci is a surrogate marker of neural rosette formation.
- Polarized neuroepithelial tissue is characterized by the presence of a coherent N-cadherin ring structure (formed by apical localization of N-cadherin) toward the center of the neuroepithelial tube and laminin, a basement membrane protein, surrounding the neuroepithelial tube on the exterior surface, contacting the hydrogel.
- the images in FIG. 8 illustrate various immunostained transverse sections of bioengineered neuroepithelial tubes prepared according to the methods of this disclosure. Basal green fluorescence is an artifact of tissue sectionmg/staining, and not equivalent to apical N-cadherin staining within the center of each section.
- biomimetic as used in connection with an engineered neuroepithelial tissue refers to a singular elongated tissue, preferably having an elliptical, tabular, or substantially tubular structure, having similarities to the anatomic structure and cytoarchitecture of the embryonic neuroepithelial tube in vivo (e.g., neural rosette-like cross-sectional structure) or transverse section thereof.
- Biomimetic elliptical neuroepithelial tissues described herein are in vitro-derived (e.g., engineered) tissues or tubes that mimic the polarized neural cytoarchitecture, with polarized NSCs displaying the apical N-cadherin expression and basal extracellular matrix protein deposition of an embryonic neural tube.
- substantially tubular means that the structure has an overall tubular configuration but need not be a perfect cylinder. In some embodiments, the structure has an overall tubular configuration that has an oval or circular shape in cross-section.
- the methods disclosed herein preferably yield a bioengineered neuroepithelial tissue organoid exhibiting a polarized rosette-like cross- sectional structure in which at least 60% of cells of a cross-section of the polarized rosette structure are Pax6+/N-cadherin+ neuroepithelial cells, wherein greater than about 75% of the bioengineered 3D neuroepithelial tissue exhibits a singular, contiguous rosette structure comparable to a developing human neuroepithelial tube.
- the expression (or lack thereof) of a number of cell type-associated markers can be used to characterize differentiation of hPSCs or NMPs into neural stem cells over the course of the practice of the methods described herein. For example, expression of some markers associated with pluripotency in hPSCs decline over the course of differentiation of hPSCs into neural stem cells. Such pluripotency markers include Oct4, Nanog, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81.
- Neuromesodermal progenitors (NMPs) have the following expression profile: SOX2 + /OCT4-/T + /PAX6-.
- NMPs During differentiation of NMPs to neural stem cells or neuronal cell types, expression of these NMP markers and other markers associated with mesoderm or endoderm also decline over time or are absent, e.g., T (Brachymy) and SOX17. Conversely expression of markers associated with neural stem cells increases over the course of differentiation. Suitable markers (at the RNA or protein level) for neural stem cells and neural differentiation include, but are not limited to, PAX6, SOX2, Nestin, N-Cadherin, and SOX1 .
- differentiation methods provided herein further include exposing cultured cells (e.g., cultured hPSCs) to a transient increase or “ boost” of Wnt/ ⁇ - catenin signaling by transiently exposing the cultured hPSCs cells to a Wnt/ ⁇ -catenin signaling agonist following about 72 hours of culture, for example, as described in U.S. Application Serial No. 14/496,796, which is incorporated by reference as if set forth in its entirety.
- cultured NMPs cells are exposed to a Wnt/p-catemn signaling “boost” following about 72 hours of culture (i.e., about 72 hours following seeding onto a micropatterned substrate).
- Wnt/ ⁇ -catenin signaling can be activated by modulating the function of one or more proteins that participate in the Wnt/ ⁇ -catenin signaling pathway to increase ⁇ -catenin expression levels or activity, TCF and LEF expression levels, or ⁇ -catenin/TCF/LEF induced transcriptional activity.
- activation of Wnt/ ⁇ -catenin signaling is achieved by inhibiting Gsk3 phosphotransferase activity or Gsk3 binding interactions.
- Gsk3 inhibition can be achieved in a variety of ways including, but not limited to, providing small molecules that inhibit Gsk3 phosphotransferase activity, RNA interference knockdown of Gsk3, and overexpression of dominant negative form of Gsk3.
- Dominant negative forms of Gsk3 are known in the art as described, e.g., in Hagen et al., 2002, J. Biol. Chem., 277: 23330-23335, which describes a Gsk3 comprising a R96A mutation, which is incorporated by reference herein in its entirety.
- Gsk3 is inhibited by contacting a cell with a small molecule that inhibits Gsk3 phosphotransferase activity or Gsk3 binding interactions.
- Suitable small molecule Gsk3 inhibitors include, but are not limited to, CHIR99021, CHIR98014, BIO- acetoxime, BIO, LiCl, SB 216763, SB 415286, AR A014418, 1-Azakenpaullone, Bis-7- indolylmaleimide, and any combinations thereof.
- any of CHIR99021, CHIR98014, and BlO-acetoxime are used to inhibit Gsk3 in pluripotent stem cells in the differentiation methods described herein.
- the small molecule Gsk3 inhibitor is CHIR99021 at a concentration ranging from about 3 ⁇ M to about 12 ⁇ M, e.g. , about 3 ⁇ M, 4 ⁇ M, 5 ⁇ M, 6 ⁇ M, 7 ⁇ M, 8 ⁇ M, 9 ⁇ M, 10 ⁇ M, 11 ⁇ M, 12 ⁇ M or another concentration of CHIR99021 from about 3 ⁇ M to about 12 ⁇ M.
- the small molecule Gsk3 inhibitor is CHIR98014 at a concentration ranging from about 0.1 ⁇ M to about 1 ⁇ M, e.g., about 0.1 ⁇ M, 0.2 ⁇ M, 0.3 ⁇ M, 0.4 ⁇ M, 0.5 ⁇ M, 0.6 ⁇ M, 0.7 ⁇ M, 0,8 ⁇ M, 0.9 ⁇ M or another concentration of CHIR98014 from about 0.1 ⁇ M to about 1 ⁇ M.
- the small molecule Gsk3 inhibitor is BlO-acetoxime at a concentration ranging from about 0.1 ⁇ M to about 1 ⁇ M, e.g., about 0.1 ⁇ M, 0.2 ⁇ M, 0.3 ⁇ M, 0.4 ⁇ M, 0.5 ⁇ M, 0.6 ⁇ M, 0.7 ⁇ M, 0.8 ⁇ M, 0.9 ⁇ M or another concentration of BlO-acetoxime from about 0.1 ⁇ M to about 1 ⁇ M.
- Gsk3 activity is inhibited by RNA interference knockdown of Gsk3.
- Gsk3 expression levels can be knocked-down using commercially available siRNAs against Gsk3, e.g., SignalSilence® GSK-3a/p siRNA (catalog #6301 from Cell Signaling Technology®, Danvers, MA), or a retroviral vector with an inducible expression cassette for Gsk3, e.g., a commercially available Tet-inducible retroviral RNA interference (RNAi) system from Clontech (Mountain View, CA, Catalog No. 630926), or a cumate-inducible system from Systems Biosciences, Inc. (Mountain View, CA), e.g., the SparQ® system, catalog no, QM200PA-2.
- RNAi Tet-inducible retroviral RNA interference
- the Wnt/ ⁇ -catenin signaling pathway is activated by overexpressing ⁇ -catenin itself, e.g, human ⁇ -catenin (exemplary nucleotide and amino acid sequences are found at GenBank Accession Nos: X87838 and CAA61107.1, respectively).
- ⁇ -catenin overexpression is achieved using an inducible expression system, e.g., any of the just-mentioned inducible expression systems.
- a constitutively active, stabilized isoform of ⁇ -catenin which contains point mutations S33A, S37A, T41A, and S45A as described, e.g, in Baba et al., 2005, Immunity 23(6):599-609, which is incorporated by reference herein in its entirety.
- Wnt/ ⁇ -catenin signaling pathway activation in pluripotent stem cells is achieved by contacting the cells with an agent that disrupts the interaction of ⁇ -catenin with Axin, a member of the ⁇ -catenin destruction complex. Disruption of the Axin/ ⁇ -catenin interaction allows ⁇ -catenin to escape degradation by the destruction complex thereby increasing the net level of ⁇ -catenin to drive ⁇ -catenin signaling.
- the Axin/ ⁇ -catenin interaction can be disrupted in pluripotent cells by contacting the cells with the compound 5-(Furan-2-yl)-N-(3-(1H-imidazol-1-yl)propyl)-1,2-oxazole-3-carboxamide (“SKL2001”), which is commercially available, e.g., as catalog no. 681667 from EMD Millipore.
- SSL2001 5-(Furan-2-yl)-N-(3-(1H-imidazol-1-yl)propyl)-1,2-oxazole-3-carboxamide
- An effective concentration of SKL2001 to activate Wnt/ ⁇ -catenin signaling ranges from about 10 ⁇ M to about 100 ⁇ M, about 20 ⁇ M, 30 ⁇ M, 40 ⁇ M, 50 ⁇ M, 60 ⁇ M, 70 ⁇ M, 80 ⁇ M, 90 ⁇ M or another concentration of SKL2001 from about 10 ⁇ M to about 100 ⁇ M.
- any appropriate method or methods can be used to confirm uniformity or the presence or absence of certain components in a biomimetic elliptical neuroepithelial tissue provided herein.
- Suitable methods for detecting the presence or absence of biological markers are well known in the art and include, without limitation, immunohistochemistry, qRT-PCR, RNA sequencing, and the like for evaluating gene expression at the RNA level.
- methods such as immunohistochemistry are used to detect and identify cell types or biomolecules within a biomimetic elliptical neuroepithelial tissue. For example, whole organoids or portions thereof can be stained for specific differentiation markers by immunohistochemistry.
- RNA sequencing can be used to obtain gene expression profiles for biomimetic elliptical neuroepithelial tissues of the invention.
- Biological markers for neuroepithelial cells include, for example, Pax6 and N-cadherin.
- Quantitative methods for evaluating expression of markers at the protein level are also known in the art. For example, flow cytometry is used to determine the fraction of cells in a given cell population that express or do not express biological markers of interest.
- any appropriate method can be used to analyze structure of engineered neuroepithelial tissues and tubes obtained according to methods of tins disclosure.
- the analytical method(s) are useful to detect the presence and identity of neurons and neuron-supporting cells (e.g., glia) in a bioengineered neuroepithelial tissue or tube.
- confocal microscopy and other microscopy-based imaging methods can be used.
- confocal microscopy can be used to collect multiple images of cross- sections of a biomimetic elliptical neuroepithelial tissue or bioengineered neuroepithelial tube that has been treated with detectably labeled antibodies or stains having specificity for various cell types present at particular stages of development of the human neural tube.
- confocal images can be obtained of cross-sections of the biomimetic elliptical neuroepithelial tissue or bioengineered neuroepithelial tube fluorescently labeled to detect N-cadherin expression (FIGS. 3, 6, and 9).
- an exemplary protocol for detecting and analyzing biomimetic elliptical neuroepithelial tissue organization includes acquiring one or more (e.g., a series of images) confocal images using a 60X objective at 1024x1024 pixels to scan through the biomimetic elliptical neuroepithelial tissue or bioengineered neuroepithelial tube in user-defined increments or steps, and analyzing a stack of the acquired confocal images to detect cell types present in or adjacent to the cellular structures using, for example, a machine learning program for image classification.
- Induced pluripotent stem cell-derived engineered biomimetic elliptical neuroepithelial tissue permits modeling of drug responses in 3D structures that recapitulate neural development in an individual having, for example, a particular genetic background or detectable phenotype. Accordingly, subject-specific human iPS cell-derived biomimetic elliptical neuroepithelial tissues are usefill to identify genetic factors and epigenetic influences that contribute to variable effects of a known or unknown drug on neural development/neural differentiation.
- Patient-specific somatic cells for reprogramming into induced pluripotent stem cells can be obtained or isolated from a target tissue of interest by biopsy or other tissue sampling methods.
- subject-specific cells are manipulated in vitro prior to use in a neuroepithelial tissue construct of the invention.
- subject-specific cells can be expanded, differentiated, genetically modified, contacted to polypeptides, nucleic acids, or other factors, cryo-preserved, or otherwise modified prior to seeding on micropatterned substrates to obtain bioengineered neuroepithelial tissues described herein.
- Standardizing culture conditions by using a chemically defined culture medium minimizes the potential for lot-to-lot or batch-to-batch variations in materials to which the cells are exposed during cell culture. Accordingly, the effects of various differentiation factors are more predictable when added to cells and tissues cultured under chemically defined conditions.
- serum-free refers to cell culture materials that are free of or substantially free of serum obtained from animal (e.g., fetal bovine) blood. In general, culturing cells or tissues in the absence of animal-derived materials (i.e., under conditions free of xenogeneic material) reduces or eliminates the potential for cross-species viral or prion transmission.
- biomimetic elliptical neuroepithelial tissues provided herein include, without limitation, in vitro screening of agents for those that modulate m vivo neural tube formation or CNS development.
- in vitro-derived biomimetic elliptical neuroepithelial tissues can be used for high throughput screening of candidate agents.
- Standardized, reproducible production of biomimetic elliptical neuroepithelial tissues can provide a revolutionary experimental paradigm for conducting personalized neuroscience studies.
- neuroepithelial organoid tissues are useful to study the effects of genetic mutations on development and function across the human CNS, to conduct personalized neuroscience studies using neural stem cells derived from induced pluripotent stem cells (iPS cells) of a particular human subject, and to assess neurotoxicity of various agents or other effects on neural development.
- iPS cells induced pluripotent stem cells
- engineered neuroepithelial tissues of the invention are useful in drag discovery and development including screening for metabolic stability, drug-drug interactions, toxicity and infectious disease.
- test agents include, without limitation, infectious agents, proteins, peptides, antibodies, small molecules, oligonucleotides, polynucleotides, peptidomimetics, cytotoxic agents, pharmaceutical agents, and xenobiotics (e.g., environmental toxin, chemical/biological warfare agent, a natural compound, and a nutraceutical).
- infectious agents e.g., infectious agents, proteins, peptides, antibodies, small molecules, oligonucleotides, polynucleotides, peptidomimetics, cytotoxic agents, pharmaceutical agents, and xenobiotics (e.g., environmental toxin, chemical/biological warfare agent, a natural compound, and a nutraceutical).
- biomimetic elliptical neuroepithelial tissues as described herein can be screened to identify agents that modulate neural tube development and development of the human CNS.
- Screening methods can comprise or consist essentially of contacting a test agent to in vitro derived bioengineered neuroepithelial tissues; and detecting an effect of the agent on bioengineered neuroepithelial tissues (e.g., disrupt or otherwise alter development of the biomimetic elliptical neuroepithelial tissues or differentiation of neural cell types within a biomimetic elliptical neuroepithelial tissue).
- screening methods include screening candidate compounds to identify test agents that promote the development of the human CNS.
- candidate compounds can be screened for toxicity to human neural cell types or tissues.
- detecting comprises detecting at least one positive or negative effect of the agent on morphology or life span of such cells and tissues, whereby an agent that increases or reduces the life span of human neural cell types or tissues, or has a positive or negative impact on the morphology of human neural cell types or tissues, is identified as having an effect on development of the human neuroepithelial tube or neural tissues.
- detecting comprises performing a method including but not limited to RNA sequencing, gene expression profiling, transcriptome analysis, cell proliferation assays, metabolome analysis, detecting reporter or sensor, protein expression profiling, Forster resonance energy transfer (FRET), metabolic profiling, and microdialysis.
- FRET Forster resonance energy transfer
- the agent can be screened for an effect on gene expression, and detecting can comprise assaying for differential gene expression relative to an uncontacted biomimetic elliptical neuroepithelial tissue.
- biomimetic elliptical neuroepithelial tissues of this disclosure are suitable as direct transplants fortissue regeneration and repair.
- detecting and/or measuring a positive or negative change in a level of expression of at least one gene following exposure (e.g., contacting) of a test compound to one or more biomimetic elliptical neuroepithelial tissues comprises whole transcriptome analysis using, for example, RNA sequencing.
- gene expression is calculated using, for example, data processing software programs such as Light Cycle, RSEM (RNA-Seq by Expectation-Maximization), Excel, and Prism. See Stewart et al., PLoS Comput. Biol. 9:e1002936 (2013), which is incorporated by reference herein in its entirety.
- RNA or protein from neural constructs. For example, total RNA can be isolated and reverse transcribed to obtain cDNA for sequencing.
- Test compounds can be dissolved in a solvent such as, for example, dimethyl sulfoxide (DMSO) prior to contacting to one or more bioengineered neuroepithelial tissues provided herein.
- identifying agents comprises analyzing the contacted bioengineered neuroepithelial tissues for positive or negative changes in biological activities including, without limitation, gene expression, protein expression, cell viability, and cell proliferation.
- microarray methods can be used to analyze gene expression profiles prior to, during, or following contacting the plurality of test compounds to the bioengineered neuroepithelial tissues.
- a method of the present invention further comprises additional analyses such as metabolic assays and protein expression profiling.
- a cell culture substrate comprising one or more components useful for obtaining an in vitro biomimetic elliptical neuroepithelial tissue or a bioengineered neuroepithelial tube.
- Components of the cell culture substrate can include one or more micropatterned substrates as described herein.
- the cell culture substrate can be a tissue culture dish, well-plate (e.g., multi-well plate), microfluidic device, or any other substrate suitable for culturing cells on the one or more micropatterned substrates to obtain an in vitro biomimetic neuroepithelial tissue.
- kits comprising one or more components usefill for obtaining an in vitro biomimetic neuroepithelial tissue or a bioengineered neuroepithelial tube.
- Components of the kit can include one or more micropatterned substrates as described herein.
- the kit can also contain a chemically defined culture medium and one or more medium additives (e.g., growth factors, small molecule compounds, culture medium supplements).
- the kit can further contain progenitor cells useful for the seeding of the micropatterned substrate and instructions for cell seeding and culture.
- kits to comprise one or more micropatterned substrates as described herein and one or more agents (e.g., growth factors, small molecule agents, agents to create a morphogen gradient) usefill to further differentiate the neuroepithelial tissue to contain various types of neurons.
- the kit can also comprise a microfluidics device or components thereof, for example, to deliver patterning agents to the bioengineered neuroepithelial tissue in a pre-determined manner.
- the kit further comprises a hydrogel suitable for use as an overlay on the biomimetic elliptical neuroepithelial tissue to obtain an encased bioengineered neuroepithelial tube according to methods of this disclosure.
- This Example demonstrates in vitro production of a biomimetic elliptical neuroepithelial tissue that contains a single polarized rosette structure that spans the length of the tissue (see FIGS. 3, 4, 5, and 6).
- FIG. 8 cross-sections of bioengineered neuroepithelial tubes produced therefrom revealed a well-organized single neural rosette of polarized N-cadherin-expressing cells spanning the length of the tissue.
- Micropattemed array substrate fabrication Micropatterned array cell culture substrates were fabricated using a combination of methods known in the art (e.g., Knight el al. , 2015, Chemical Communications 51 ;5238-241; Sha et al., 2013, Biomacromolecules 14: 3294- 3303, which are incorporated by reference herein in their entirety). Polydimethylsiloxane (PDMS) stamps with arrays of post and micro-well features were generated as relief molds of silicon wafers. (FIG. 1). The wafers were designed in AutoCAD and purchased from FlowJEM (available at flowjem.com).
- PDMS Polydimethylsiloxane
- PDMS stamps were coated with ®-mercaptoundecyl bromoisobutyrate (2 mM in 100% ethanol), dried under inert gas, and then brought in conformal contact with glass coverslips coated with 180 nm gold (Au) atop 30 nm titanium (Ti). Micropatemed slides were then incubated in 100% ethanol for 10 min, prior to being dried under nitrogen and transferred to a Schlenk flask under vacuum.
- PEG-MEMA polyethylene glycol) methyl ether methacrylate
- methanol obtained from Thermo Fisher
- copper(II) bromide Sigma Aldrich
- 2 ’,2 -bipyridine Sigma Aldrich
- SI-ATRP Surface-initiated atom -transfer radical -polymerization
- Polymerization was terminated via addition of air and followed by rinsing with ethanol and water before drying under inert gas.
- the substrates were rinsed five times with sterile PBS (Thermo Fisher) and transferred to individual wells of a 12-well tissue-culture polystyrene (TCPS) plate where they were rendered cell-adhesive through adsorption of 0.083 mg/mL Matrigel (WiCell) m DMEM/F-12 (Thermo Fisher) via overnight incubation at 37°C. (FIG. 2).
- Results showing generation of single fused neural rosette tissue and neuroepithelial tissue, including neuroepithelial tubes are described in detail below and in corresponding FIGS. 2-8, as provided below:
- hPSC-derived micropatterned tissues To generate hPSC-derived micropatterned tissues, hPSC cultures at -85% confluency were rinsed with PBS, dissociated with Accutase for 5 min at 37°C and collected via centrifugation at 1000 rpm for 5 min. (FIGS. 2-3). Singularized hPSCs were then suspended in E8 media with 10 ⁇ M ROCK inhibitor and seeded onto micropatterned substrates at 165,000 cells/cm 2 in 2 ml of media per well in a 12-well plate. The following day the media was replaced with 2 mL of E6 media and 50% media changes were performed daily thereafter. (FIG. 4). By Day 5, micropatterned neural tissue fusions spanned an entire row on the micropatterned arrays. (FIG. 5).
- Circular micropaterns separated by 50 ⁇ m from edge-to-edge and with bridges fonned a contiguous, fused tissue with a single N-cadherin + rosette polarization across the entire row of micropatterned array, starting to form a three dimensional tub with apical N-cadherin expression over 5 days m culture. (FIG. 6).
- Matrigel encapsulation of micropattemed forebrain neuroepithelial tissues Upon tissue fusion and rosette alignment (Day 5 or 6), 750 ⁇ L neuroepithelial tissue media was removed using a P1000 micropipette and replaced with 750 ⁇ L of Matrigel at 4°C. (FIG. 7). Matrigel gelation was then conducted via incubation at 37°C for 20 min. (FIG. 7). Once gelled, 1 mL of E6 media is pipeted into each well and placed back in the incubator. The following day, sterile forceps were used to detach the layer of Matrigel from the walls of the tissue culture plate. (FIG. 8).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21904325.4A EP4259779A1 (en) | 2020-12-08 | 2021-12-08 | Methods for controlled induction of bioengineered neuroepithelial tissues and 3-d neuroepithelial tubes |
JP2023534986A JP2023553110A (en) | 2020-12-08 | 2021-12-08 | Method for controlling and guiding neuroepithelial tissue and 3D neuroepithelial tubes using bioengineering |
CA3200399A CA3200399A1 (en) | 2020-12-08 | 2021-12-08 | Methods for controlled induction of bioengineered neuroepithelial tissues and 3-d neuroepithelial tubes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063122918P | 2020-12-08 | 2020-12-08 | |
US63/122,918 | 2020-12-08 | ||
US202063127974P | 2020-12-18 | 2020-12-18 | |
US63/127,974 | 2020-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022125654A1 true WO2022125654A1 (en) | 2022-06-16 |
Family
ID=81848548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/062390 WO2022125654A1 (en) | 2020-12-08 | 2021-12-08 | Methods for controlled induction of bioengineered neuroepithelial tissues and 3-d neuroepithelial tubes |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220177853A1 (en) |
EP (1) | EP4259779A1 (en) |
JP (1) | JP2023553110A (en) |
CA (1) | CA3200399A1 (en) |
WO (1) | WO2022125654A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190024046A1 (en) * | 2017-07-24 | 2019-01-24 | Wisconsin Alumni Research Foundation | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures |
US20200115677A1 (en) * | 2018-10-16 | 2020-04-16 | Wisconsin Alumni Research Foundation | Methods for controlled induction of 3d cylindrical neuroepithelial tubes |
-
2021
- 2021-12-08 JP JP2023534986A patent/JP2023553110A/en active Pending
- 2021-12-08 US US17/545,416 patent/US20220177853A1/en active Pending
- 2021-12-08 WO PCT/US2021/062390 patent/WO2022125654A1/en active Application Filing
- 2021-12-08 CA CA3200399A patent/CA3200399A1/en active Pending
- 2021-12-08 EP EP21904325.4A patent/EP4259779A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190024046A1 (en) * | 2017-07-24 | 2019-01-24 | Wisconsin Alumni Research Foundation | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures |
US20200115677A1 (en) * | 2018-10-16 | 2020-04-16 | Wisconsin Alumni Research Foundation | Methods for controlled induction of 3d cylindrical neuroepithelial tubes |
Also Published As
Publication number | Publication date |
---|---|
CA3200399A1 (en) | 2022-06-16 |
JP2023553110A (en) | 2023-12-20 |
EP4259779A1 (en) | 2023-10-18 |
US20220177853A1 (en) | 2022-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7154546B2 (en) | Method for producing retinal tissue | |
KR102368751B1 (en) | Method for manufacturing ciliary margin stem cells | |
CN107438669A (en) | For the production method and composition of the stem cell-derived dopaminergic cell for treating nerve degenerative diseases | |
KR102210180B1 (en) | Method for producing ciliary marginal zone-like structure | |
US20230383247A1 (en) | Methods and Culture Substrates for Controlled Induction of Biomimetic Neural Tissues Comprising Singular Rosette Structures | |
CN105849254A (en) | Method for purification of retinal pigment epithelial cells | |
Shariati et al. | Organoid technology: Current standing and future perspectives | |
JP2011250791A (en) | Cell culture | |
JPWO2019017492A1 (en) | Method for maturing retinal tissue containing continuous epithelium | |
KR20130112862A (en) | Cardiomyocyte medium with dialyzed serum | |
JP6416622B2 (en) | Adhesion signature based method for isolating stem cells and cells derived from stem cells | |
ES2617086T3 (en) | Method for the identification of a modulator of a cellular signaling | |
JPWO2019021990A1 (en) | Small intestinal epithelial-like cells | |
JP2013512671A (en) | Selection of stem cell clones with defined differentiation potential | |
US20210222123A1 (en) | In vitro expansion of dopaminergic subtype neuronal progenitors derived from pluripotent stem cells | |
US11390846B2 (en) | Methods for controlled induction of 3D cylindrical neuroepithelial tubes | |
Amit et al. | Atlas of human pluripotent stem cells: derivation and culturing | |
JP2022531761A (en) | Nociceptor differentiation from human pluripotent stem cells | |
US20220177853A1 (en) | Methods for controlled induction of bioengineered neuroepithelial tissues and 3-d neuroepithelial tubes | |
Stathakos et al. | Imaging autophagy in hiPSC-derived midbrain dopaminergic neuronal cultures for Parkinson’s disease research | |
Simon et al. | Differentiation of EpiLCs on micropatterned substrates generated by micro-contact printing | |
JP2022504764A (en) | Compositions and Methods for Cell Culture | |
JP7446242B2 (en) | Cell population containing embryonic erythroblasts and its production method, cell culture composition, and compound testing method | |
WO2023037986A1 (en) | Method for producing pluripotent stem cells | |
TW201832114A (en) | Evaluating method and selecting method of induced pluripotent stem cells, and manufacturing method of induced pluripotent stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21904325 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3200399 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023534986 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021904325 Country of ref document: EP Effective date: 20230710 |